Deals

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager
Multi-specific antibodiesNASDAQ: ZYME

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Zymeworks Inc. (NASDAQ: ZYME) announced that it has entered into an exclusive global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a novel trispecific…

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CRO / CMO / CDMOHarbour BioMed

Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics

Chronic diseaseE-commerce

JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration

Smart medical care; wearables; IoTViVest Medical Technology

ViVest Medical Raises Funds for Wearable Cardioverter Defibrillator Development

Chronic diseaseWolters Kluwer

Wolters Kluwer Partners with China’s NCID to Advance Infectious Disease Diagnosis

Show More